NYSE:OGEN Oragenics (OGEN) Stock Price, News & Analysis → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free OGEN Stock Alerts $1.67 -0.05 (-2.91%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$1.66▼$1.7750-Day Range$1.01▼$3.0952-Week Range$1.00▼$7.74Volume33,100 shsAverage Volume105,746 shsMarket Capitalization$7.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Oragenics alerts: Email Address Ad Smallcaps DailyIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closelyLearn how this American company is leading the lithium-ion revolution About Oragenics Stock (NYSE:OGEN)Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Read More OGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OGEN Stock News HeadlinesJune 3, 2024 | americanbankingnews.comOragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.comMay 22, 2024 | globenewswire.comOragenics Appoints William “Frank” Peacock MD as Chief Clinical OfficerMay 17, 2024 | globenewswire.comOragenics, Inc. to Host Webinar Panel on Neurotrauma MedicineMay 16, 2024 | msn.comOragenics climbs 9% amid Phase 2 study, business updatesMay 16, 2024 | finance.yahoo.comOragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion TrialMay 16, 2024 | investorplace.comOGEN Stock Earnings: Oragenics Reported Results for Q1 2024May 11, 2024 | finance.yahoo.comOragenics, Inc. (OGEN)May 7, 2024 | msn.comOragenics partners with Avance Clinical for Phase 2 concussion studyMay 7, 2024 | finance.yahoo.comOragenics Partners with Avance Clinical for Phase II Concussion Trial in AustraliaApril 27, 2024 | finance.yahoo.comOragenics, Inc. (OGEN) Stock Price, News, Quote & History - Yahoo FinanceApril 20, 2024 | finance.yahoo.comOdyssey Health, Inc. (ODYY)April 19, 2024 | businesswire.comOragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsApril 17, 2024 | money.usnews.comOragenics IncApril 16, 2024 | ca.finance.yahoo.comOragenics, Inc. (OGEN) Latest Stock News & Headlines - Yahoo FinanceApril 1, 2024 | finance.yahoo.comOragenics, Inc. Files 10K and Provides Company UpdateMarch 18, 2024 | markets.businessinsider.comOragenics Appoints Kelly As Chief Medical OfficerMarch 17, 2024 | finance.yahoo.com15 Highest Quality Probiotics For Gut HealthMarch 5, 2024 | businesswire.comOragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat ConcussionMarch 1, 2024 | businesswire.comOragenics Announces Closing of Public OfferingMarch 1, 2024 | uk.investing.comOragenics announces public stock offeringFebruary 28, 2024 | investorplace.comWhy Is Oragenics (OGEN) Stock Down 45% Today?February 27, 2024 | markets.businessinsider.comOragenics Prices Public Offering Of 1.40 Mln Shares At $1.50/shr; Stock PlungesFebruary 27, 2024 | businesswire.comOragenics Announces Pricing of Public OfferingFebruary 27, 2024 | marketwatch.comOragenics Shares Fall After Proposed Public OfferingFebruary 27, 2024 | businesswire.comOragenics Announces Proposed Public OfferingSee More Headlines Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:OGEN Previous SymbolNYSE:OGEN CUSIPN/A CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,660,000.00 Net MarginsN/A Pretax Margin-96,485.71% Return on Equity-615.16% Return on Assets-325.98% Debt Debt-to-Equity RatioN/A Current Ratio2.69 Quick Ratio2.69 Sales & Book Value Annual Sales$40,000.00 Price / Sales187.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book2.74Miscellaneous Outstanding Shares4,480,000Free Float3,379,000Market Cap$7.48 million OptionableN/A Beta0.58 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Charles L. Pope CPA (Age 72)Executive Chairman Comp: $112.5kMr. Joseph Michael Redmond (Age 63)President & Interim Principal Executive Officer Ms. Janet Huffman (Age 52)CFO, Secretary & Treasurer Comp: $314.9kDr. James P. Kelly M.A.M.D., Chief Medical Officer & Member of Scientific AdvisorKey CompetitorsMarker TherapeuticsNASDAQ:MRKRUnicycive TherapeuticsNASDAQ:UNCYBolt BiotherapeuticsNASDAQ:BOLTAcasti PharmaNASDAQ:ACSTEquilliumNASDAQ:EQView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 22,675 shares on 5/20/2024Ownership: 0.506%Fred TellingSold 3,500 sharesTotal: $12,495.00 ($3.57/share)View All Insider TransactionsView All Institutional Transactions OGEN Stock Analysis - Frequently Asked Questions How have OGEN shares performed in 2024? Oragenics' stock was trading at $6.1382 on January 1st, 2024. Since then, OGEN stock has decreased by 72.8% and is now trading at $1.67. View the best growth stocks for 2024 here. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSE:OGEN) posted its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.70) earnings per share for the quarter. When did Oragenics' stock split? Oragenics's stock reverse split on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Yunji (YJ), MFA Financial (MFA) and Who are Oragenics' major shareholders? Oragenics' stock is owned by many different institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.51%). Insiders that own company stock include Fred Telling, Michael O'keefe Sullivan and Robert C Koski. View institutional ownership trends. How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:OGEN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.